The role of epigenetics in malignant pleural mesothelioma

[en] Malignant pleural mesothelioma (MPM) is an almost invariably fatal cancer of the pleura due to asbestos exposure. Increasing evidence indicates that unresponsiveness to chemotherapy is due to epigenetic errors leading to inadequate gene expression in tumor cells. The availability of compounds that modulate epigenetic modifications, such as histone acetylation or DNA methylation, offers new prospects for treatment of MPM. Here, we review latest findings on epigenetics in mesothelioma and present novel strategies for promising epigenetic thérapies.

Disciplines :

Oncology

Author, co-author :

Vandermeers, Fabian

Neelature Sriramareddy, Sathyanarayana ; Université de Liège - ULiège

Chrisostome, Costa

Hubaux, Roland

Cosse, Jean-Philippe ; Université de Liège - ULiège > GIGA-R : Epigénétique Cellulaire et Moléculaire

Willems, Luc ; Université de Liège - ULiège > Chimie et bio-industries > Biologie cell. et moléc.

Language :

English

Title :

The role of epigenetics in malignant pleural mesothelioma

Publication date :

2013

Journal title :

Lung Cancer

ISSN :

0169-5002

eISSN :

1872-8332

Publisher :

Elsevier Scientific, Limerick, Ireland

Volume :

Pages :

311-318

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

This work was supported by the “Fonds National de la Recherche Scientifique” (FNRS), the Télévie, the Belgian Foundation against Cancer, the Sixth Research Framework Programme of the European Union (project INCA LSHC-CT-2005-018704), the “Neoangio” excellence program and the “Partenariat Public Privé” PPP INCA of the “Direction générale des Technologies, de la Recherche et de l’Energie/DG06” of the Walloon government, the “Action de Recherche Concertée Glyvir” of the “Communauté franc¸ aise de Belgique”, the “Centre anticancéreux près ULg” (CAC), the “Synbiofor” project of GxABT, the “ULg Fonds Spéciaux pour la Recherche”, the “Plan Cancer” of the “Service Public Fédéral,” and the Interuniversity Attraction Poles (IAP) Program BELVIR initiated by the Belgian Science Policy Office.

Available on ORBi :

since 22 August 2013

Statistics

Number of views

80 (20 by ULiège)

Number of downloads

3 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Wagner J.C., Sleggs C.A., Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960, 17:260-271. [Epub 1960/10/01].
La Vecchia C., Boffetta P. Role of stopping exposure and recent exposure to asbestos in the risk of mesothelioma. Eur J Cancer Prev 2012, 21(3):227-230. [Epub 2012/02/09].
Peto J., Decarli A., La Vecchia C., Levi F., Negri E. The European mesothelioma epidemic. Br J Cancer 1999, 79(3-4):666-672. [Epub 1999/02/23].
Lange J.H. Re: "Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003". Am J Epidemiol 2004, 160(8):823. [Epub 2004/10/07].
Morinaga K., Kishimoto T., Sakatani M., Akira M., Yokoyama K., Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 2001, 39(2):65-74. [Epub 2001/05/09].
Price B., Ware A. Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 2004, 159(2):107-112. [Epub 2004/01/14].
Pasello G., Ceresoli G.L., Favaretto A. An overview of neoadjuvant chemotherapy in the multimodality treatment of malignant pleural mesothelioma. Cancer Treat Rev 2012, [Epub 2012/03/31].
Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644. [Epub 2003/07/16].
Jassem J., Ramlau R., Santoro A., Schuette W., Chemaissani A., Hong S., et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008, 26(10):1698-1704. [Epub 2008/04/01].
Kindler H.L., Millard F., Herndon J.E., Vogelzang N.J., Suzuki Y., Green M.R. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31(2-3):311-317. [Epub 2001/02/13].
Stebbing J., Powles T., McPherson K., Shamash J., Wells P., Sheaff M.T., et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009, 63(1):94-97. [Epub 2008/05/20].
van Meerbeeck J.P., Baas P., Debruyne C., Groen H.J., Manegold C., Ardizzoni A., et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999, 85(12):2577-2582. [Epub 1999/06/22].
Holliday R. DNA methylation and epigenetic inheritance. Philos Trans R Soc Lond B Biol Sci 1990, 326(1235):329-338. [Epub 1990/01/30].
Kornberg R.D., Lorch Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 1999, 98(3):285-294. [Epub 1999/08/24].
Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389(6648):251-260. [Epub 1997/09/26].
Bird A.P. CpG-rich islands and the function of DNA methylation. Nature 1986, 321(6067):209-213. [Epub 1986/05/15].
Craig J.M., Bickmore W.A. The distribution of CpG islands in mammalian chromosomes. Nat Genet 1994, 7(3):376-382. [Epub 1994/07/01].
Kristensen L.S., Nielsen H.M., Hansen L.L. Epigenetics and cancer treatment. Eur J Pharmacol 2009, 625(1-3):131-142. [Epub 2009/10/20].
Chen T., Ueda Y., Dodge J.E., Wang Z., Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003, 23(16):5594-5605. [Epub 2003/08/05].
Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99(3):247-257. [Epub 1999/11/11].
Allfrey V.G., Faulkner R., Mirsky A.E. Acetylation and methylation of histones and their possible role in the regulation of rna synthesis. Proc Natl Acad Sci U S A 1964, 51:786-794. [Epub 1964/05/01].
Hong L., Schroth G.P., Matthews H.R., Yau P., Bradbury E.M. Studies of the DNA binding properties of histone H4 amino terminus. Thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA. J Biol Chem 1993, 268(1):305-314. [Epub 1993/01/05].
Norton V.G., Imai B.S., Yau P., Bradbury E.M. Histone acetylation reduces nucleosome core particle linking number change. Cell 1989, 57(3):449-457. [Epub 1989/05/05].
Parra M.A., Wyrick J.J. Regulation of gene transcription by the histone H2A N-terminal domain. Mol Cell Biol 2007, 27(21):7641-7648. [Epub 2007/08/29].
Pogo B.G., Allfrey V.G., Mirsky A.E. RNA synthesis and histone acetylation during the course of gene activation in lymphocytes. Proc Natl Acad Sci U S A 1966, 55(4):805-812. [Epub 1966/04/01].
Sealy L., Chalkley R. DNA associated with hyperacetylated histone is preferentially digested by DNase I. Nucleic Acids Res 1978, 5(6):1863-1876. [Epub 1978/06/01].
Sims R.J., Nishioka K., Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet 2003, 19(11):629-639. [Epub 2003/10/31].
Grozinger C.M., Schreiber S.L. Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 2002, 9(1):3-16. [Epub 2002/02/14].
Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1(3):194-202. [Epub 2002/03/21].
de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370(Pt 3):737-749. [Epub 2002/11/14].
Maze I., Nestler E.J. The epigenetic landscape of addiction. Ann N Y Acad Sci 2011, 1216:99-113. [Epub 2011/01/29].
Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159. [Epub 2008/03/14].
Kondo Y., Shen L., Cheng A.S., Ahmed S., Boumber Y., Charo C., et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008, 40(6):741-750. [Epub 2008/05/20].
Guo X.W., Th'ng J.P., Swank R.A., Anderson H.J., Tudan C., Bradbury E.M., et al. Chromosome condensation induced by fostriecin does not require p34cdc2 kinase activity and histone H1 hyperphosphorylation, but is associated with enhanced histone H2A and H3 phosphorylation. EMBO J 1995, 14(5):976-985. [Epub 1995/03/01].
Barth T.K., Imhof A. Fast signals and slow marks: the dynamics of histone modifications. Trends Biochem Sci 2010, 35(11):618-626. [Epub 2010/08/06].
Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005, 45:629-656. [Epub 2005/04/12].
Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004, 4(2):143-153. [Epub 2004/01/21].
Hatziapostolou M., Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 2011, 68(10):1681-1702. [Epub 2011/01/21].
Tysnes B.B. Tumor-initiating and -propagating cells: cells that we would like to identify and control. Neoplasia 2010, 12(7):506-515. [Epub 2010/07/24].
Dobrovic A., Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997, 57(16):3347-3350. [Epub 1997/08/15].
Esteller M. The necessity of a human epigenome project. Carcinogenesis 2006, 27(6):1121-1125. [Epub 2006/05/16].
Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349(21):2042-2054. [Epub 2003/11/25].
Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991, 48(5):880-888. [Epub 1991/05/01].
Fraga M.F., Esteller M. Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 2005, 4(10):1377-1381. [Epub 2005/10/06].
Halkidou K., Gaughan L., Cook S., Leung H.Y., Neal D.E., Robson C.N. Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004, 59(2):177-189. [Epub 2004/03/26].
Mercurio C., Minucci S., Pelicci P.G. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010, 62(1):18-34. [Epub 2010/03/12].
Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 2005, 113(4):264-268. [Epub 2005/05/04].
Zhang Z., Yamashita H., Toyama T., Sugiura H., Ando Y., Mita K., et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat 2005, 94(1):11-16. [Epub 2005/09/21].
Baris I., Simonato L., Artvinli M., Pooley F., Saracci R., Skidmore J., et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int J Cancer 1987, 39(1):10-17. [Epub 1987/01/15].
Comin C.E., de Klerk N.H., Henderson D.W. Malignant mesothelioma: current conundrums over risk estimates and whither electron microscopy for diagnosis?. Ultrastruct Pathol 1997, 21(4):315-320. [Epub 1997/07/01].
Gazdar A.F., Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 2003, 5(3):177-181. [Epub 2003/12/12].
Muscat J.E., Wynder E.L. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res 1991, 51(9):2263-2267. [Epub 1991/05/01].
Tischoff I., Neid M., Neumann V., Tannapfel A. Pathohistological diagnosis and differential diagnosis. Recent Results Cancer Res 2011, 189:57-78. [Epub 2011/04/12].
Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997, 145(3):211-218. [Epub 1997/02/01].
van Meerbeeck J.P., Gaafar R., Manegold C., Van Klaveren R.J., Van Marck E.A., Vincent M., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005, 23(28):6881-6889. [Epub 2005/09/30].
Gordon G.J., Jensen R.V., Hsiao L.L., Gullans S.R., Blumenstock J.E., Richards W.G., et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 2003, 95(8):598-605. [Epub 2003/04/17].
Gordon G.J., Rockwell G.N., Jensen R.V., Rheinwald J.G., Glickman J.N., Aronson J.P., et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005, 166(6):1827-1840. [Epub 2005/05/28].
Christensen B.C., Houseman E.A., Godleski J.J., Marsit C.J., Longacker J.L., Roelofs C.R., et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009, 69(1):227-234. [Epub 2009/01/02].
Goto Y., Shinjo K., Kondo Y., Shen L., Toyota M., Suzuki H., et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009, 69(23):9073-9082. [Epub 2009/11/06].
Christensen B.C., Godleski J.J., Marsit C.J., Houseman E.A., Lopez-Fagundo C.Y., Longacker J.L., et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008, 29(8):1555-1559. [Epub 2008/03/04].
Kohno H., Amatya V.J., Takeshima Y., Kushitani K., Hattori N., Kohno N., et al. Aberrant promoter methylation of WIF-1 and SFRP1, 2, 4 genes in mesothelioma. Oncol Rep 2010, 24(2):423-431. [Epub 2010/07/03].
Kubo T., Toyooka S., Tsukuda K., Sakaguchi M., Fukazawa T., Soh J., et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011, 17(15):4965-4974. [Epub 2011/06/16].
Amatori S., Papalini F., Lazzarini R., Donati B., Bagaloni I., Rippo M.R., et al. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 2009, 66(2):184-190. [Epub 2009/02/24].
Kassis E.S., Zhao M., Hong J.A., Chen G.A., Nguyen D.M., Schrump D.S. Depletion of DNA methyltransferase 1 and/or DNA methyltransferase 3b mediates growth arrest and apoptosis in lung and esophageal cancer and malignant pleural mesothelioma cells. J Thorac Cardiovasc Surg 2006, 131(2):298-306. [Epub 2006/01/26].
Nelson H.H., Almquist L.M., LaRocca J.L., Plaza S.L., Lambert-Messerlian G.M., Sugarbaker D.J., et al. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. Epigenetics 2011, 6(8):1029-1034. [Epub 2011/07/22].
Hollevoet K., Reitsma J.B., Creaney J., Grigoriu B.D., Robinson B.W., Scherpereel A., et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012, 30(13):1541-1549. [Epub 2012/03/14].
Fischer J.R., Ohnmacht U., Rieger N., Zemaitis M., Stoffregen C., Kostrzewa M., et al. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006, 54(1):109-116. [Epub 2006/08/09].
Tsou J.A., Galler J.S., Wali A., Ye W., Siegmund K.D., Groshen S., et al. DNA methylation profile of 28 potential marker loci in malignant mesothelioma. Lung Cancer 2007, 58(2):220-230. [Epub 2007/07/31].
Bertrand P. Inside HDAC with HDAC inhibitors. Eur J Med Chem 2010, 45(6):2095-2116. [Epub 2010/03/13].
Kim H.J., Bae S.C. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res 2011, 3(2):166-179. [Epub 2011/03/19].
Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1(4):287-299. [Epub 2002/07/18].
Catalano M.G., Fortunati N., Pugliese M., Marano F., Ortoleva L., Poli R., et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2012, [Epub 2012/05/09].
Jin G., Bausch D., Knightly T., Liu Z., Li Y., Liu B., et al. Histone deacetylase inhibitors enhance endothelial cell sprouting angiogenesis in vitro. Surgery 2011, 150(3):429-435. [Epub 2011/09/01].
Osuka S., Takano S., Watanabe S., Ishikawa E., Yamamoto T., Matsumura A. Valproic acid inhibits angiogenesis in vitro and glioma angiogenesis in vivo in the brain. Neurol Med Chir (Tokyo) 2012, 52(4):186-193. [Epub 2012/04/24].
Lindemann R.K., Newbold A., Whitecross K.F., Cluse L.A., Frew A.J., Ellis L., et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007, 104(19):8071-8076. [Epub 2007/05/02].
Carlisi D., Lauricella M., D'Anneo A., Emanuele S., Angileri L., Di Fazio P., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer 2009, 45(13):2425-2438. [Epub 2009/08/01].
Neuzil J., Swettenham E., Gellert N. Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. Biochem Biophys Res Commun 2004, 314(1):186-191. [Epub 2004/01/13].
Crisanti M.C., Wallace A.F., Kapoor V., Vandermeers F., Dowling M.L., Pereira L.P., et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 2009, 8(8):2221-2231. [Epub 2009/08/13].
Symanowski J., Vogelzang N., Zawel L., Atadja P., Pass H., Sharma S. A histone deacetylase inhibitor LBH589 downregulates XIAP in mesothelioma cell lines which is likely responsible for increased apoptosis with TRAIL. J Thorac Oncol 2009, 4(2):149-160. [Epub 2009/01/31].
Cao X.X., Mohuiddin I., Ece F., McConkey D.J., Smythe W.R. Histone deacetylase inhibitor downregulation of bcl-xl gene expression leads to apoptotic cell death in mesothelioma. Am J Respir Cell Mol Biol 2001, 25(5):562-568. [Epub 2001/11/20].
Mohiuddin I., Cao X., Fang B., Nishizaki M., Smythe W.R. Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma. Cancer Gene Ther 2001, 8(8):547-554. [Epub 2001/09/26].
Vandermeers F., Hubert P., Delvenne P., Mascaux C., Grigoriu B., Burny A., et al. Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin Cancer Res 2009, 15(8):2818-2828. [Epub 2009/04/09].
Yamauchi Y., Izumi Y., Asakura K., Fukutomi T., Serizawa A., Kawai K., et al. Lovastatin and valproic acid additively attenuate cell invasion in ACC-MESO-1 cells. Biochem Biophys Res Commun 2011, 410(2):328-332. [Epub 2011/06/16].
Amatori S., Bagaloni I., Viti D., Fanelli M. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma. Lung Cancer 2011, 71(1):113-115. [Epub 2010/11/26].
Takenouchi M., Hirai S., Sakuragi N., Yagita H., Hamada H., Kato K. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts. Clin Cancer Res 2011, 17(9):2819-2829. [Epub 2011/03/02].
Ranzato E., Martinotti S., Magnelli V., Murer B., Biffo S., Mutti L., et al. Epigallocatechin-3-gallate induces mesothelioma cell death via H(2) o(2) -dependent T-type Ca(2+) channel opening. J Cell Mol Med 2012, [Epub 2012/05/09].
Wang Y., Rishi A.K., Wu W., Polin L., Sharma S., Levi E., et al. Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem 2011, 357(1-2):83-94. [Epub 2011/05/20].
Yamauchi Y., Izumi Y., Asakura K., Hayashi Y., Nomori H. Curcumin Induces Autophagy in ACC-MESO-1 Cells. Phytother Res 2012, [Epub 2012/03/06].
Sigalotti L., Coral S., Altomonte M., Natali L., Gaudino G., Cacciotti P., et al. Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002, 86(6):979-982. [Epub 2002/04/16].
Weiser T.S., Guo Z.S., Ohnmacht G.A., Parkhurst M.L., Tong-On P., Marincola F.M., et al. Sequential 5-Aza-2 deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother 2001, 24(2):151-161. [Epub 2001/03/27].
Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., et al. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur Respir J 2011, 38(5):1105-1116. [Epub 2011/05/05].
Guillot F., Boutin B., Blanquart C., Fonteneau J.F., Robard M., Gregoire M., et al. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth. Vaccine 2011, 29(33):5534-5543. [Epub 2011/05/31].
Roulois D., Blanquart C., Panterne C., Gueugnon F., Gregoire M., Fonteneau J.F. Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur J Immunol 2012, 42(3):783-789. [Epub 2011/12/07].
Ramalingam S.S., Belani C.P., Ruel C., Frankel P., Gitlitz B., Koczywas M., et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009, 4(1):97-101. [Epub 2008/12/20].
Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23(17):3912-3922. [Epub 2005/04/27].
Krug L.M., Curley T., Schwartz L., Richardson S., Marks P., Chiao J., et al. Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. Clin Lung Cancer 2006, 7(4):257-261. [Epub 2006/03/04].
Barbone D., Cheung P., Battula S., Busacca S., Gray S.G., Longley D.B., et al. Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PloS ONE 2012, 7(12):e52753. [Epub 2013/01/10].
NJV L.Chen, Blumenschein G., Robert F., Pluda J.M., Frankel S.R., Sharma S. Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer. J Clin Oncol 2007, 25(18S):18088.
Scherpereel A., Berghmans T., Lafitte J.J., Colinet B., Richez M., Bonduelle Y., et al. Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011, 37(1):129-135. [Epub 2010/06/10].